Fennec Pharmaceuticals Inc. (FENNC) is a respected biopharmaceutical company that specializes in advancing treatments for cancer and other significant unmet medical needs. FENNC is dedicated to a relentless pursuit of efficiency and innovation in improving the quality of life and long-term outcomes of patients worldwide. Beyond its commitment to research and development, the company seeks to create value by leveraging its experience and capabilities to develop a portfolio of innovative products to address the needs of patients.
Established in 2003, the company, formerly known as Adherex Technologies Inc., changed its name to Fennec Pharmaceuticals Inc. in September 2014. The decision to change the company name reflected a broader restructuring plan to more effectively align the company's brand with its core mission of patient-focused pharmaceutical innovation. Headquartered in Research Triangle Park in North Carolina, USA, and with an additional office in Ontario, Canada, Fennec Pharmaceuticals operates at the cutting edge of biotechnological advances.
Fennec Pharmaceuticals Inc's flagship product is PEDMARK (a unique formulation of Sodium Thiosulfate). PEDMARK has demonstrated compelling efficacy in reducing ototoxicity (ear toxicity) caused by cisplatin in a pivotal Phase 3 clinical study in children. Cisplatin is a potent chemotherapy drug used in numerous pediatric malignancies; however, it can cause severe problems, including hearing loss. By addressing this significant unmet need, the company aims to substantially improve these patients' quality of life.
Following the successful outcome of the Phase 3 clinical trials for PEDMARK, Fennec Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 2020, seeking approval for the drug's use in preventing cisplatin-related ototoxicity in pediatric patients. This submission marked an important milestone in the company's history.
Equipped with its promising drug portfolio coupled with the dedication of its competent team and strategic collaborations, Fennec Pharmaceuticals Inc continues to maintain its competitive edge while contributing significantly to the field of medicine. The company is dedicated to achieving distinct advances in care for patients who have limited or inadequate treatment options. The leadership at FENNC is persistently focused on enhancing shareholder value while taking steps toward the attainment of important goals in transformative health care. Their unwavering commitment to innovation and quality care makes Fennec Pharmaceuticals a shining star in the biopharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Fennec Pharmaceuticals announced positive results from its Phase 2 STS-J01 clinical study of PEDMARK in Japan, showing a significant reduction in cisplatin-induced hearing loss in pediatric and young adult cancer patients. Only 24% of patients experienced ASHA-defined hearing loss compared to a 56.4% historical benchmark, with no severe hearing loss reported and robust tumor responses observed. Fennec is now pursuing regulatory registration in Japan and exploring partnering opportunities for PEDMARK.
Rosty Raykov, a former director of Fennec Pharmaceuticals Inc., reported two recent transactions involving the company's common shares. He acquired 2,778 restricted shares at no cost on August 31, 2026, and subsequently sold 10,000 common shares at $12.11 each on September 1, 2026, under a pre-established Rule 10b5-1 trading plan. Following these transactions, Raykov's direct holdings in Fennec Pharmaceuticals decreased to 124,411 shares.
Fennec Pharmaceuticals Inc. has appointed Jessica Vargas as Vice President of Human Resources, bringing significant experience in HR business partnering and talent acquisition. Vargas will be responsible for the company’s people strategy, organizational development, and culture, supporting Fennec's mission to improve patient outcomes. Her extensive background includes roles at Amgen, Horizon, Graphic Packaging International, and Fenwal, Inc., spanning approximately 18 years in HR.
This article provides an AI-generated analysis of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), indicating strong near and mid-term sentiment that could extend to the long term, with no resistance levels above the current price suggesting upside potential. It outlines specific institutional trading strategies (Long, Breakout, Short) with entry, target, and stop-loss levels, and a multi-timeframe signal analysis highlighting support and resistance. The analysis emphasizes positive sentiment and offers real-time signals and risk parameters.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) recently released its second-quarter report, significantly beating revenue and EPS expectations with US$18m and US$0.05 respectively. Following these strong results, analysts have updated their forecasts, increasing revenue predictions to US$72.9m and EPS to US$0.32 for 2026, and raising the price target by 13% to US$17.67. The company is also expected to grow faster than the wider industry.